PCRX Pacira Biosciences Inc.

Pacira BioSciences to Present at the 2021 Barclays Global Healthcare Conference

Pacira BioSciences to Present at the 2021 Barclays Global Healthcare Conference

PARSIPPANY, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: PCRX) today announced that it will present at the 2021 Barclays Global Healthcare Conference at 10:55 AM ET on Tuesday, March 9, 2021. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at . A replay of the webcast will also be available for two weeks following the event.

About Pacira         

Pacira BioSciences, Inc. (Nasdaq: PCRX) is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, Pacira acquired the iovera°® system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit .



Company Contact:
Pacira BioSciences, Inc.
Christian Pedetti
(973) 254-4387
EN
03/03/2021

Underlying

PCRXPacira Biosciences Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacira Biosciences Inc.

 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira to Report Second Quarter 2025 Financial Results on Tuesday Augu...

Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025 BRISBANE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its second quarter financial results after the close of the U.S. markets on Tuesday August 5, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answ...

July 24, 2025 1 EN
 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira BioSciences Announces Strategic Collaboration to Significantly ...

Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts Partnership expected to advance 5x30 strategy by increasing ZILRETTA sales calls and extensively expanding patient access BRISBANE, CA, July 22, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced a strategic collaboration1 with Johnson & Johnson MedTech to significantly expand the market reach of ZILRETTA® (triamcinolone acetonide extended-...

July 22, 2025 1 EN
 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on July 2, 2025 to seven new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), th...

July 3, 2025 1 EN
 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’...

Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025 - Produced for Pacira by BBC StoryWorks Commercial Productions, The Next Frontier: Mark & Leah’s Story Highlights the Impact of Non-Opioid Solutions - BRISBANE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the debut of a powerful new spotlighting the journey of a couple who, after navigating t...

June 18, 2025 1 EN
 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira BioSciences Unveils Three-Year Clinical Data Following a Single...

Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee -- PCRX-201 demonstrated sustained clinical efficacy with improvements in pain, stiffness, and function for up to three years – BRISBANE, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced new long-term follow-up data from its Phase ...

June 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch